SCHEDULE: T. Rowe Price Discloses 5.5% Stake in MediWound Ltd

T. Rowe Price Associates, Inc. has reported beneficial ownership of 5.5% of MediWound Ltd's common stock as of March 31, 2026.

Summary

• T. Rowe Price Associates, Inc. has filed a Schedule 13G, indicating it beneficially owns 709,847 shares of MediWound Ltd common stock.
• This ownership stake represents 5.5% of the total class of securities.
• The filing date for this report is May 15, 2026, with the event date requiring the filing being March 31, 2026.
• T. Rowe Price Associates, Inc. is identified as an investment adviser.
• The company explicitly denies beneficial ownership for the purpose of changing or influencing control of MediWound Ltd.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While T. Rowe Price's investment is a positive signal of institutional interest, the passive nature of the Schedule 13G and the explicit denial of control intent temper any strong positive or negative sentiment.

Positives

• T. Rowe Price Associates, Inc., a significant investment entity, has taken a notable stake in MediWound Ltd, potentially signaling confidence in the company's future prospects.
• The filing indicates a substantial ownership percentage (5.5%), which could lead to increased institutional interest and potential share price appreciation.

Negatives

• The filing is a Schedule 13G, which is an 'initial beneficial ownership filing' by passive investors. This means T. Rowe Price is not seeking to influence or control the company, which could be interpreted as a lack of strong conviction for active engagement.
• The explicit denial of beneficial ownership for control purposes might suggest that this stake is part of a broader portfolio management strategy rather than a deep commitment to MediWound's strategic direction.

Risks

• The primary risk is that T. Rowe Price Associates, Inc. may decide to divest its stake, which could lead to downward pressure on MediWound Ltd's stock price.
• As a passive investor, T. Rowe Price's involvement does not guarantee any strategic support or active advocacy for MediWound Ltd's management or business initiatives.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from MediWound Ltd. It is a disclosure of ownership by T. Rowe Price Associates, Inc.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

StockSavvy.ai notes that the acquisition of a significant passive stake by a major asset manager like T. Rowe Price Associates, Inc. in a biotechnology or medical device company like MediWound Ltd is a common occurrence. Such filings often precede or coincide with increased analyst coverage or market interest, but the passive nature of the filing suggests it's more about portfolio allocation than direct strategic influence.

Stakeholder Impact

• Shareholders: The increased institutional ownership may lead to greater liquidity and potentially more stable share price performance, but also carries the risk of significant selling pressure if T. Rowe Price decides to exit its position.
• Management: The passive nature of the investment means T. Rowe Price is unlikely to exert direct pressure on management decisions, allowing the current leadership to continue its strategic direction without significant external influence from this specific holder.

Next Steps

• T. Rowe Price Associates, Inc. will continue to hold its shares in MediWound Ltd, subject to its investment strategy.
• MediWound Ltd may see increased analyst coverage or investor interest due to the institutional ownership.

Key Dates

Keywords

MediWound Ltd, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Institutional Investor